MARKET

LIXT

LIXT

Lixte Biotechnology Hldgs Inc
NASDAQ
1.220
+0.010
+0.83%
Closed 15:02 03/17 EDT
OPEN
1.210
PREV CLOSE
1.210
HIGH
1.240
LOW
1.210
VOLUME
12.09K
TURNOVER
0
52 WEEK HIGH
4.400
52 WEEK LOW
1.020
MARKET CAP
3.27M
P/E (TTM)
-0.6863
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LIXT last week (0310-0314)?
Weekly Report · 22h ago
LIXTE BIOTECHNOLOGY HOLDINGS INC - SALES AGREEMENT TERMINATION EFFECTIVE MARCH 18, 2025
Reuters · 6d ago
Lixte announces online publication of new pre-clinical data in BioXriv
TipRanks · 03/10 12:40
Weekly Report: what happened at LIXT last week (0303-0307)?
Weekly Report · 03/10 11:46
Weekly Report: what happened at LIXT last week (0224-0228)?
Weekly Report · 03/03 11:45
Lixte Biotechnology adds Lurie Cancer Center as second site in LB-100 trial
TipRanks · 02/25 13:56
LIXTE ADDS NORTHWESTERN UNIVERSITY’S LURIE CANCER CENTER AS SECOND SITE IN ONGOING CLINICAL TRIAL FOR OVARIAN CLEAR CELL CANCER
Reuters · 02/25 13:30
Weekly Report: what happened at LIXT last week (0217-0221)?
Weekly Report · 02/24 11:45
More
About LIXT
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Webull offers Lixte Biotechnology Holdings Inc stock information, including NASDAQ: LIXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIXT stock methods without spending real money on the virtual paper trading platform.